Anthony O. Caggiano,Anindita Ganguly,Jennifer Iaci,Tom Parry
申请号：
US15940250
公开号：
US20180280477A1
申请日:
2018.03.29
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
